Probenecid inhibits SARS-CoV-2 replication in vivo and in vitro

Jackelyn Murray; Robert J. Hogan; David E. Martin; Kathy Blahunka; Fred D. Sancilio; Rajiv Balyan; Mark Lovern; Richard Still; Ralph A. Tripp

doi:10.1038/s41598-021-97658-w

Probenecid inhibits SARS-CoV-2 replication in vivo and in vitro

Jackelyn Murray
, Robert J. Hogan
, David E. Martin
, Kathy Blahunka
, Fred D. Sancilio
, Rajiv Balyan
, Mark Lovern
, Richard Still
, Ralph A. Tripp

Research output: Contribution to journal › Article › peer-review

34 Citations (Scopus)

37 Downloads (Pure)

Abstract

Effective vaccines are slowing the COVID-19 pandemic, but SARS-CoV-2 will likely remain an issue in the future making it important to have therapeutics to treat patients. There are few options for treating patients with COVID-19. We show probenecid potently blocks SARS-CoV-2 replication in mammalian cells and virus replication in a hamster model. Furthermore, we demonstrate that plasma concentrations up to 50-fold higher than the protein binding adjusted IC₉₀ value are achievable for 24 h following a single oral dose. These data support the potential clinical utility of probenecid to control SARS-CoV-2 infection in humans.

Original language	English
Article number	18085
Pages (from-to)	1-7
Number of pages	7
Journal	Scientific Reports
Volume	11
Issue number	1
DOIs	https://doi.org/10.1038/s41598-021-97658-w
Publication status	Published - Dec 2021
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1038/s41598-021-97658-wLicence: CC BY

ArticleFinal published version, 1.42 MBLicence: CC BY

Cite this

@article{9de77b21bdf44ae49a6fca58088541d5,

title = "Probenecid inhibits SARS-CoV-2 replication in vivo and in vitro",

abstract = "Effective vaccines are slowing the COVID-19 pandemic, but SARS-CoV-2 will likely remain an issue in the future making it important to have therapeutics to treat patients. There are few options for treating patients with COVID-19. We show probenecid potently blocks SARS-CoV-2 replication in mammalian cells and virus replication in a hamster model. Furthermore, we demonstrate that plasma concentrations up to 50-fold higher than the protein binding adjusted IC90 value are achievable for 24 h following a single oral dose. These data support the potential clinical utility of probenecid to control SARS-CoV-2 infection in humans.",

author = "Jackelyn Murray and Hogan, \{Robert J.\} and Martin, \{David E.\} and Kathy Blahunka and Sancilio, \{Fred D.\} and Rajiv Balyan and Mark Lovern and Richard Still and Tripp, \{Ralph A.\}",

note = "Funding Information: The authors would like to thank Phil Young and Billy Meadow for their advice. This work was funded in part by the Georgia Research Alliance and SpinUp Campus. Publisher Copyright: {\textcopyright} 2021, The Author(s).",

year = "2021",

month = dec,

doi = "10.1038/s41598-021-97658-w",

language = "English",

volume = "11",

pages = "1--7",

journal = "Scientific Reports",

issn = "2045-2322",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - Probenecid inhibits SARS-CoV-2 replication in vivo and in vitro

AU - Murray, Jackelyn

AU - Hogan, Robert J.

AU - Martin, David E.

AU - Blahunka, Kathy

AU - Sancilio, Fred D.

AU - Balyan, Rajiv

AU - Lovern, Mark

AU - Still, Richard

AU - Tripp, Ralph A.

N1 - Funding Information: The authors would like to thank Phil Young and Billy Meadow for their advice. This work was funded in part by the Georgia Research Alliance and SpinUp Campus. Publisher Copyright: © 2021, The Author(s).

PY - 2021/12

Y1 - 2021/12

N2 - Effective vaccines are slowing the COVID-19 pandemic, but SARS-CoV-2 will likely remain an issue in the future making it important to have therapeutics to treat patients. There are few options for treating patients with COVID-19. We show probenecid potently blocks SARS-CoV-2 replication in mammalian cells and virus replication in a hamster model. Furthermore, we demonstrate that plasma concentrations up to 50-fold higher than the protein binding adjusted IC90 value are achievable for 24 h following a single oral dose. These data support the potential clinical utility of probenecid to control SARS-CoV-2 infection in humans.

AB - Effective vaccines are slowing the COVID-19 pandemic, but SARS-CoV-2 will likely remain an issue in the future making it important to have therapeutics to treat patients. There are few options for treating patients with COVID-19. We show probenecid potently blocks SARS-CoV-2 replication in mammalian cells and virus replication in a hamster model. Furthermore, we demonstrate that plasma concentrations up to 50-fold higher than the protein binding adjusted IC90 value are achievable for 24 h following a single oral dose. These data support the potential clinical utility of probenecid to control SARS-CoV-2 infection in humans.

UR - https://www.scopus.com/pages/publications/85114891172

U2 - 10.1038/s41598-021-97658-w

DO - 10.1038/s41598-021-97658-w

M3 - Article

C2 - 34508172

AN - SCOPUS:85114891172

SN - 2045-2322

VL - 11

SP - 1

EP - 7

JO - Scientific Reports

JF - Scientific Reports

IS - 1

M1 - 18085

ER -

Probenecid inhibits SARS-CoV-2 replication in vivo and in vitro

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this